1,182
Views
0
CrossRef citations to date
0
Altmetric
Articles

Experimental in vivo model to evaluate the impact of Cernitin™ on pain response on induced chronic bladder inflammation

, ORCID Icon, , &
Pages 320-328 | Received 29 Mar 2022, Accepted 13 Jun 2022, Published online: 29 Jun 2022

Figures & data

Table 1. Experimental design.

Figure 1. Experimental designs used in the study. Vehicles 1 and 2, gabapentin and test substances as indicated in . was administered on day (D) 7, D8, D9 and D10. Von Frey test was first performed at day 7 (before pharmacological treatment) to confirm presence of visceral pain and then at day 10 to analyze compounds effect on CYP-induced chronic bladder pain.

Figure 1. Experimental designs used in the study. Vehicles 1 and 2, gabapentin and test substances as indicated in Table 1. was administered on day (D) 7, D8, D9 and D10. Von Frey test was first performed at day 7 (before pharmacological treatment) to confirm presence of visceral pain and then at day 10 to analyze compounds effect on CYP-induced chronic bladder pain.

Figure 3. Mean expression level of COX-2 and MCP-1 in the bladder tissue homogenates. (A) a significant decrease in COX-2 levels was observed in the Cernitin™T60 (**p < .01) and Cernitin™ GBX (*p < .05) groups compared to vehicle-treated groups, combination treatment did not enhance the effect of Cernitin™ (*p < .05). (B) MCP-1 levels remained unchanged. Gabapentin (Gaba)-treated group produced a significant reduction of COX-2 level (*p < .05). Data are presented as mean ± SD (n = 5).

Figure 3. Mean expression level of COX-2 and MCP-1 in the bladder tissue homogenates. (A) a significant decrease in COX-2 levels was observed in the Cernitin™T60 (**p < .01) and Cernitin™ GBX (*p < .05) groups compared to vehicle-treated groups, combination treatment did not enhance the effect of Cernitin™ (*p < .05). (B) MCP-1 levels remained unchanged. Gabapentin (Gaba)-treated group produced a significant reduction of COX-2 level (*p < .05). Data are presented as mean ± SD (n = 5).

Table 2. Hematoxylin–eosin staining analyses of tissue sections for presence of bladder inflammation and edema performed in five animals from each treatment group.

Figure 4. Immunohistochemical analysis of the bladder tissues. Effects of Cernitin™ on the expression of (A) CD45, (B) PGD2 and (C) SP. T + G = T60 + GBX. Immunostaining was performed in the five animals mentioned in . intensity was determined by color intensity as follows; strongly stained as score 3, moderately stained as score 2 and weakly stained as score 1, no staining as score 0.

Figure 4. Immunohistochemical analysis of the bladder tissues. Effects of Cernitin™ on the expression of (A) CD45, (B) PGD2 and (C) SP. T + G = T60 + GBX. Immunostaining was performed in the five animals mentioned in Table 2. intensity was determined by color intensity as follows; strongly stained as score 3, moderately stained as score 2 and weakly stained as score 1, no staining as score 0.